Compare PTLE & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTLE | SCLX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | 34 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 48.5M |
| IPO Year | N/A | N/A |
| Metric | PTLE | SCLX |
|---|---|---|
| Price | $4.70 | $6.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 90.0K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $4.20 |
| 52 Week High | $16.17 | $34.27 |
| Indicator | PTLE | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 38.40 |
| Support Level | $0.13 | $4.20 |
| Resistance Level | $9.00 | $7.77 |
| Average True Range (ATR) | 0.64 | 0.88 |
| MACD | -0.09 | -0.25 |
| Stochastic Oscillator | 10.57 | 8.23 |
PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, serving the Asia Pacific market. The company's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers on time; and handling disputes, mainly concerning quality and quantity issues on marine fuel. The company derives its maximum revenue from Hong Kong.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.